Please try another search
Progenics Pharmaceuticals, Inc., an oncology company, engages in the development and commercialization of various targeted medicines and artificial intelligence to find, fight, and follow cancer. The company’s commercial products comprise AZEDRA for the treatment of patients with unresectable locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy; and oral and subcutaneous formulations of RELISTORfor the treatment of opioid-induced constipation. Its products also include AZEDRA, 1095, and PSMA TTC that are therapeutic agents to treat cancer; prostate-specific membrane antigen targeted imaging agents for prostate cancer; and imaging analysis technology. The company was founded in 1986 and is headquartered in New York, New York. Progenics Pharmaceuticals, Inc. is a subsidiary of Lantheus Holdings, Inc.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review